{
    "clinical_study": {
        "@rank": "35356", 
        "brief_summary": {
            "textblock": "To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir,\n      antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune\n      adjuvant in HIV-seropositive patients. To investigate the effect of increasing doses of\n      Proleukin on the time to progression of CMV retinitis in patients being treated with\n      therapeutic ganciclovir and antiretroviral therapy. To evaluate the incidence and level of\n      anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient\n      population."
        }, 
        "brief_title": "A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will receive subcutaneous Proleukin in combination with ganciclovir and\n      antiretroviral therapy, and the MTD will be determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n        Documented HIV seropositivity.\n\n        Prior Medication:\n\n        Required:\n\n          -  FDA-approved antiretroviral therapy for at least 2 months prior to study entry.\n\n        Allowed:\n\n          -  Prior G-CSF."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002321", 
            "org_study_id": "086A", 
            "secondary_id": "CS-L293-10"
        }, 
        "intervention": {
            "intervention_name": "Aldesleukin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ganciclovir", 
                "Aldesleukin"
            ]
        }, 
        "keyword": [
            "Retinitis", 
            "Interleukin-2", 
            "Ganciclovir", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toledo", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43699"
                }, 
                "name": "Med College of Ohio"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002321"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiron Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1994"
    }, 
    "geocoordinates": {
        "Med College of Ohio": "41.664 -83.555"
    }
}